Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088901 | 0.89 | TRPA1 (0.50) | ADORA2ATRPA1METAP2RXRARXRB | |
| SCHEMBL20085908 | 0.86 | ADORA2A (0.45) | ADORA2ATRPA1METAP2 | |
| SCHEMBL20088957 | 0.86 | TRPA1 (0.38) | ADORA2ATRPA1RXRARXRBRXRG | |
| SCHEMBL20088890 | 0.82 | ADORA2A (0.37) | ADORA2ATRPA1METAP2 | |
| SCHEMBL20088985 | 0.81 | TRPA1 (0.50) | ADORA2ATRPA1RXRARXRBRXRG | |
| SCHEMBL20088904 | 0.80 | ADORA2A (0.41) | ADORA2ATRPA1METAP2RXRARXRB | |
| SCHEMBL20085902 | 0.78 | ADORA2A (0.40) | ADORA2AMETAP2 | |
| SCHEMBL20088903 | 0.77 | ADORA2A (0.44) | ADORA2ATRPA1RXRARXRBRXRG | |
| SCHEMBL20085907 | 0.77 | ADORA2A (0.42) | ADORA2ATRPA1RXRARXRBRXRG | |
| SCHEMBL20089163 | 0.76 | TRPA1 (0.54) | ADORA2ATRPA1METAP2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | claimed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| WO-2018080916-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111942-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | ADORA2A 135/4885TRPA1 1234/4885METAP2 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.